Akero Therapeutics CEO Andrew Cheng's 2022 pay jumps 135% to $10M

Akero Therapeutics reports 2022 executive compensation

By ExecPay News

Published: April 28, 2023

Akero Therapeutics reported fiscal year 2022 executive compensation information on April 28, 2023.
In 2022, five executives at Akero Therapeutics received on average a compensation package of $5.4M, a 134% increase compared to previous year.
Average pay of disclosed executives at Akero Therapeutics
Andrew Cheng, Chief Executive Officer, received $10M in total, which increased by 135% compared to 2021. 67% of Cheng's compensation, or $7M, was in option awards. Cheng also received $601K in non-equity incentive plan, $624K in salary, as well as $2.2M in stock awards.
For fiscal year 2022, the median employee pay was $515,516 at Akero Therapeutics. Therefore, the ratio of Andrew Cheng's pay to the median employee pay was 20 to one.
Timothy Rolph, DPhil, Chief Scientific Officer, received a compensation package of $4.2M, which increased by 135% compared to previous year. 61% of the compensation package, or $2.6M, was in option awards.
William White, Chief Financial Officer, earned $4.1M in 2022, a 133% increase compared to previous year.
Jonathan Young, Chief Operating Officer, received $4.1M in 2022, which increases by 131% compared to 2021.
Catriona Yale, Chief Development Officer, earned $4.1M in 2022, a 136% increase compared to previous year.

Related executives

Andrew Cheng

Akero Therapeutics

Chief Executive Officer

William White

Akero Therapeutics

Chief Financial Officer

Jonathan Young

Akero Therapeutics

Chief Operating Officer

Timothy DPhil

Akero Therapeutics

Chief Scientific Officer

Catriona Yale

Akero Therapeutics

Chief Development Officer

You may also like

Source: SEC filing on April 28, 2023.